Navigation Links
Spike in testicular cancer is focus

Pinpointing reasons behind the dramatic increase in testicular cancer, now the most common malignant cancer among 15-to-35-year-old Caucasian men, is the focus of a five-year, $5.5 million National Cancer Institute (NCI) grant to Yale Public Health researcher Tongzhang Zheng.

Testicular cancer is increasing for unknown reasons and this study will provide important information on possible environmental, genetic and other risk factors,?said Zheng, professor and head of the Division of Environmental Health Sciences in the Department of Epidemiology and Public Health at Yale School of Medicine.

Zheng will collaborate with researchers at Harvard School of Public Health and the Fred Hutchinson Cancer Research Center to conduct a population-based, case-control study on men in Connecticut and Massachusetts. The researchers will determine whether exposure to environmental factors such as environmental hormone disruptors increases the risk of testicular cancer. They will measure the levels of these environmental compounds in 800 patients with testicular cancer and in an equal number of unaffected control subjects.

Because so little is known about the potential environmental causes of testicular cancer, Zheng said, the team will collect and evaluate information on various major suspected risk factors, such as past medical history, history of hernia, venereal diseases, and any medication with androgens and other hormones. They will also examine lifetime occupational history, tobacco smoking, alcohol consumption and dietary information.

“Recent studies show that environmental exposures may affect development of testicular cancer,?said Zheng. “Determining risk factors that lead to testicular cancer, however is complicated because genetic susceptibility may modify a person’s risk from environmental exposures. We will try to assess the potential gene environment interaction on the manifestations of the disease.?


'"/>

Source:Yale University


Page: 1

Related biology news :

1. Study hints at role of stem cell genes in testicular, breast cancers
2. Viral DNA sequence a possible trigger for breast cancer
3. Enzyme, lost in most mammals, is shown to protect against UV-induced skin cancer
4. Its not all genetic: Common epigenetic problem doubles cancer risk in mice
5. Columbia research lifts major hurdle to gene therapy for cancer
6. Combination therapy boosts effectiveness of telomere-directed cancer cell death
7. Mitochondrial DNA mutations play significant role in prostate cancer
8. New imaging method gives early indication if brain cancer therapy is effective, U-M study shows
9. BRCA1 causes ovarian cancer through indirect, biochemical route
10. Researchers identify target for cancer drugs
11. Weizmann Institute scientists develop a new approach for directing treatment to metastasized prostate cancer in the bones.
Post Your Comments:
*Name:
*Comment:
*Email:


(Date:11/22/2016)... Nov. 22, 2016   MedNet Solutions , an ... spectrum of clinical research, is pleased to announce that ... Healthcare and Life Sciences Awards as "Most Outstanding ... an unprecedented year of recognition and growth for MedNet, ... 15 years. iMedNet ™ , ...
(Date:11/16/2016)... Nov. 16, 2016 Sensory Inc ., ... security for consumer electronics, and VeriTran , ... retail industry, today announced a global partnership that ... to authenticate users of mobile banking and mobile ... software which requires no specialized biometric scanners, ...
(Date:6/27/2016)... Research and Markets has announced the addition ... to their offering. The report ... to grow at a CAGR of 12.28% during the period 2016-2020. ... in-depth market analysis with inputs from industry experts. The report covers ... The report also includes a discussion of the key vendors operating ...
Breaking Biology News(10 mins):
(Date:12/8/2016)... ... December 08, 2016 , ... ... World Technology Awards. uBiome is one of just six company finalists in the ... In addition to uBiome, companies nominated as finalists in this year’s awards include ...
(Date:12/8/2016)... N.J. , Dec. 8, 2016 Soligenix, ... biopharmaceutical company focused on developing and commercializing products to ... need, announced today that it will be hosting an ... am ET on the origins of innate defense regulators ... a review of oral mucositis and the recently announced ...
(Date:12/8/2016)... Eutilex Co. Ltd. today announced that it ... A financing. This financing round included participation from DS ... Bio Angel. This new funding brings the total capital ... since its founding in 2015. The ... commercialization of its immuno-oncology programs, expand its R&D capabilities ...
(Date:12/7/2016)... San Diego (PRWEB) , ... December 07, 2016 ... ... safety data from its phase I/II dose escalation and expansion clinical trial for ... 2016 in Vienna, Austria. The purpose of the trial was to determine the ...
Breaking Biology Technology: